Literature DB >> 24740462

Diagnostic validity of colchicine in patients with Familial Mediterranean fever.

Fatih Ozaltin1, Yelda Bilginer, Bora Gülhan, Inci Bajin, Ozlem Erdogan, Mutlu Hayran, Engin Yılmaz, Seza Ozen.   

Abstract

Although response to colchicine has been proposed as one of the diagnostic criteria in patients with Familial Mediterranean fever (FMF), the validity of this response has not been validated. The aim of this study was to assess the efficacy of the response to colchicine and to evaluate the extent of the effect of placebo. A double-blind randomized placebo-controlled trial with a cross-over design was conducted. The frequency of FMF attacks, the disease score, physical examination, and acute phase reactants were assessed at 0, 3, and 6 months. Blood samples were collected for complete blood count (CBC), erythrocyte sedimentation rate (ESR), levels of serum C-reactive protein (CRP) and serum amyloid A (SAA), and MEFV mutation analysis in 79 patients with a preliminary diagnosis of FMF. Patients were randomly allocated to receive either drug A or drug B in a double-blind fashion. The designated drug was switched at 3 months. Patients taking colchicine had less frequent FMF attacks (median 0) and lower FMF disease score (median 0) when compared to those on placebo (median 1 and 3, respectively) (p = 0.002 and p = 0.007, respectively). In genetically confirmed FMF patients, median attack number and median disease score was 0 under colchicine treatment, whereas these parameters were significantly higher in the placebo group (median 2 and 8, respectively) (p = 0.007 and p = 0.02, respectively) suggesting that colchicine is more effective than placebo in reducing attacks and disease score. Positive and negative predictive values were 70.2 and 37.5 %, respectively. During the placebo period, patients had less FMF attacks when compared to that of the pre-study period (median 2 vs 6, respectively) (p < 0.001). The high false positive rate raises concerns for considering the colchicine response test as diagnostic for FMF. The role of placebo on the attacks of periodic fever syndromes needs to be further investigated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24740462     DOI: 10.1007/s10067-014-2598-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  The powerful placebo.

Authors:  H K BEECHER
Journal:  J Am Med Assoc       Date:  1955-12-24

2.  Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population.

Authors:  E Yilmaz; S Ozen; B Balci; A Duzova; R Topaloglu; N Besbas; U Saatci; A Bakkaloglu; M Ozguc
Journal:  Eur J Hum Genet       Date:  2001-07       Impact factor: 4.246

3.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

Review 4.  Therapy of autoinflammatory syndromes.

Authors:  Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

Review 5.  Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment.

Authors:  A Hróbjartsson; P C Gøtzsche
Journal:  J Intern Med       Date:  2004-08       Impact factor: 8.989

6.  Familial Mediterranean fever: clinical, molecular and management advancements.

Authors:  M Lidar; A Livneh
Journal:  Neth J Med       Date:  2007-10       Impact factor: 1.422

7.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

Review 8.  Placebo interventions for all clinical conditions.

Authors:  Asbjørn Hróbjartsson; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 9.  Placebo interventions for all clinical conditions.

Authors:  A Hróbjartsson; P C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2004

10.  Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.

Authors:  A Duzova; A Bakkaloglu; N Besbas; R Topaloglu; S Ozen; F Ozaltin; Y Bassoy; E Yilmaz
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.